Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09
A Phase I, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects
Sponsor: Arbor Pharmaceuticals, Inc.
Terminated
Study stopping criteria was met
Other terminated trials from Arbor Pharmaceuticals, Inc.
More terminations from Arbor Pharmaceuticals, Inc.
A PHASE1 clinical study on Anesthesia, this trial is terminated or withdrawn. The trial is conducted by Arbor Pharmaceuticals, Inc. and has accumulated 7 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — May 2022 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arbor Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .